Becton Dickinson (BD)

Becton, Dickinson and Company (BD) is one of the largest medical technology companies in the world, with a history stretching back to 1897 when Maxwell Becton and Fairleigh Dickinson founded the business in New York. Listed on the New York Stock Exchange under the ticker BDX and a constituent of the S&P 500, BD operates across more than 190 countries and employs approximately 65,000 people globally.

BD's Three Core Segments

BD organises its business into three principal segments. BD Medical covers medication management and drug delivery, encompassing syringes, infusion systems, and prefillable drug delivery devices. BD Diagnostics focuses on specimen collection, microbiology, and diagnostic instrumentation, including the widely used BD Vacutainer blood collection systems. BD Life Sciences serves researchers and clinical laboratories with flow cytometry platforms, reagents, and cell biology tools, anchored by the long-established BD Biosciences portfolio.

Diagnostics, Infection Prevention & Integrated Solutions

BD has a particularly strong reputation in infection prevention and diagnostic accuracy. Its specimen management systems are standard equipment in hospitals and reference laboratories worldwide. The 2017 acquisition of C. R. Bard significantly expanded BD's presence in vascular access, oncology, and urology, making vascular care one of the company's largest revenue contributors. The BD Alaris infusion platform is among the most widely deployed medication delivery systems in acute care settings globally.

The company invests substantially in research and development, with a focus on integrated diagnostics, smart medication management, and connected care. BD's digital and software capabilities have grown through its BD BodyGuard and BD Pyxis medication dispensing platforms, which are embedded in hospital pharmacy and nursing workflows across North America and increasingly in international markets.

Headquartered in Franklin Lakes, New Jersey, BD reports annual revenues exceeding $19 billion, placing it firmly among the leading medical technology companies by scale. Its manufacturing and R&D footprint spans sites in the United States, Europe, and Asia Pacific, supporting both proprietary production and partnership-based supply chains.

Further information is available at bd.com.